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SOCIAL NETWORKING IN THE AGE OF PERSONAL GENOMICS 
SANDRA SOO-JIN LEE* 
The beginning of the 21st century has ushered in a much-heralded era 
of personal genomics that presents new challenges to the regulation of 
human genetic testing.  Personal genomics builds upon human genetic 
variation research—the area of study that attempts to identify how genetic 
differences may be associated with the onset of disease or the expression of 
a human trait or condition.1  Based upon initial results from genome-wide 
association studies, dozens of companies now offer “personalized” genetic 
tests for a widening range of complex conditions and traits, including, for 
example, the analysis of genetic ancestry, or the determination of relative 
risk for developing, for example, colon cancer.2  Many within the scientific 
community have joined an active debate over the validity and utility of 
personal genomics for the individual consumer, with some expressing 
skepticism over the potential public health benefits of personal genomics.3  
 
* Sandra Soo-Jin Lee, Ph.D., is a medical anthropologist and Senior Research Scholar at the 
Center for Biomedical Ethics at Stanford University Medical School.  Funding for this article 
was provided by a grant from the National Human Genome Research Institute, National 
Institutes of Health (P50 #HG003389).  Dr. Lee would like to thank the participants at the 
Saint Louis University Health Law Symposium, “Living in the Genetic Age: New Issues, New 
Challenges,” for their helpful comments and suggestions on the presentation on which this 
article is based. 
 1. See Elizabeth Pennisi, Breakthrough of the Year: Human Genetic Variation, 318 
SCIENCE 1842, 1842 (2007).  See also Jocelyn Kaiser, It’s All About Me, 318 SCIENCE 1843, 
1843 (2007). 
 2. Sarah E. Gollust et al., Direct-to-Consumer Sales of Genetic Services on the Internet, 
5 GENETICS MED. 332, 333 (2003); Katrina A.B. Goddard et al., Awareness and Use of 
Direct-to-Consumer Nutrigenomic Tests, United States, 2006, 9 GENETICS MED. 510, 510 
(2007). 
 3. See, e.g., Deborah A. Bolnick et al., The Science and Business of Genetic Ancestry 
Testing, 318 SCIENCE 399, 399-400 (explaining that genetic ancestry tests often provide 
information about only a few of the customer’s ancestors); Wylie Burke, Genetic Testing, 347 
NEW ENG. J. MED. 1867, 1871-72 (2002) (noting that because some disorders may have 
different causes, testing for all possible mutations may be prohibitively expensive); Sarah E. 
Gollust et al., Limitations to Direct-to-Consumer Advertising for Clinical Genetic Testing, 288 
JAMA 1762, 1762-63 (2002) (arguing for increased regulation of advertisements for genetic 
tests); David J. Hunter et al., Letting the Genome Out of the Bottle – Will We Get Our Wish?, 
358 NEW ENG. J. MED. 105, 106 (2008) (explaining that “even very small error rates per SNP, 
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Whether personal genomics will ultimately improve health outcomes 
remains to be seen, yet what is disturbingly clear is that the current 
infrastructure of regulation has not kept pace with capitalization of emerging 
technology for personal genetic services and products.  As personal 
genomic testing is introduced to and taken up by the public, it is imperative 
to consider and anticipate long-term ethical concerns over genetic testing.  
It is equally important to consider novel uses of personal genomics that may 
include purposes outside of the realm of clinical issues as they may prove 
critical to the creation of new regulatory guidelines aimed at protecting both 
commercial innovation and public health. 
Since the completion of the Human Genome Project, the unexpected 
precipitous decline in the cost of genetic sequencing has resulted in a 
proliferation of companies which now market products and services that 
provide personal genetic information directly to consumers.4  The 
development of increasingly efficient high-throughput genetic sequencing 
technologies in concert with ubiquitous Internet use by the public has laid 
the foundation for these commercial developments.5  This combination of 
factors may foreshadow several paradigm shifts in how the public consumes 
personal genetic information. 
The direct-to-consumer (DTC) marketplace articulates these shifts as 
stemming from changes in public desire for personal genomics.6  The first of 
 
magnified across the genome, can result in hundreds of misclassified variants for any 
individual patient”); Linda L. McCabe & Edward R.B. McCabe, Direct-to-Consumer Genetic 
Testing: Access and Marketing, 6 GENETICS MED. 58, 58-59 (2004) (explaining that 
consumers are not able to adequately analyze direct-to-consumer marketing); Roxanne 
Mykitiuk, Caveat Emptor: Direct-to-Consumer Supply and Advertising of Genetic Testing, 27 
CLINICAL & INVESTIGATIVE MED. 23, 25-26 (2004) (noting how the misunderstanding of genetic 
information can lead to improper and unhealthy lifestyle adjustments); Christopher H. Wade & 
Benjamin S. Wilfond, Ethical and Clinical Practice Considerations for Genetic Counselors 
Related to Direct-to-Consumer Marketing of Genetic Tests, 142C AM. J. MED. GENETICS 284, 
285-86 (2006) (noting that “the literature on risk factors for common diseases is often 
inconsistent due to the publication of gene-disease associations that turn out to be spurious”); 
Adam J. Wolfberg, Genes on the Web – Direct-to-Consumer Marketing of Genetic Testing, 
355 NEW ENG. J. MED. 543, 543-44 (2006) (noting critics’ concern that the companies are 
exploiting consumers’ anxiety in order to sell them unnecessary tests). 
 4. See Kaiser, supra note 1, at 1843.  See also Gollust et al., supra note 3, at 1762. 
 5. See generally, Gollust et al., supra note 2, at 332 (discussing the availability of direct-
to-consumer genetic services); Mykitiuk, supra note 3, at 23 (discussing issues of direct-to-
consumer genetic tests in Canada). 
 6. Amy L. McGuire et al., Social Networkers’ Attitudes Toward Direct-to-Consumer 
Personal Genome Testing, AM. J. BIOETHICS, June 2009, at 3, 4-5 (noting that sixty-four 
percent of respondents to a survey “indicated that they would consider using [personal 
genome tests] in the future” and that forty percent of respondents found personal genome tests 
appealing because they can “learn about their genetic make-up without having to go through 
a physician”). 
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these claims is that knowledge of a person’s genetic code is “empowering” 
and will enable individuals to make better decisions about lifestyle, health, 
and medical care.7  The second is that a new era of “openness” challenges 
traditional approaches to genetic testing, requiring a different ethical 
framework towards public protection.8  This position suggests a new attitude 
towards personal information and individual privacy.  And, the third claim 
argues that in a context where large population-based DNA collections are 
needed to fuel genomic research, industry will play a critical role in scaling-
up the collection of genotypic and phenotypic information needed for large 
cohort genetic studies.9  Although these predictions have yet to be validated 
as only time will tell, it is imperative to consider what questions these 
putative shifts may generate in anticipating effective and timely regulation of 
the capitalization of emerging genomic technologies. 
I.  THE RISE OF DTC PERSONAL GENOMICS 
Two years after the company 23andMe, Inc. launched in 2006,10 Time 
Magazine named 23andMe’s DNA-testing service “Time’s 2008 Invention 
of the Year.”11  Anita Hamilton, an author for Time Magazine wrote, “We 
are [only] at the beginning of a personal-genomics[sic] revolution that will 
transform not only how we take care of ourselves but also what we mean by 
personal information.”12  The California-based 23andMe, which was 
founded by Linda Avey and Anne Wojcicki, has become a leader in a 
burgeoning industry aimed at offering genetic testing directly to consumers 
over the Internet.13  Funded by Google, Inc., Genentech, Inc., and New 
 
 7. See Bryn Williams-Jones, ‘Be Ready Against Cancer, Now’: Direct-to-Consumer 
Advertising for Genetic Testing, 25 NEW GENETICS & SOC’Y 89, 91 (2006). 
 8. See generally Katherine Wasson et al., Direct-to-Consumer Online Genetic Testing 
and the Four Principles: An Analysis of the Ethical Issues, 22 ETHICS & MED. 83, 83, 90 (2006) 
(discussing how uncertainty regarding the accuracy and reliability of direct-to-consumer 
genetic tests raises moral and ethical considerations).  See also Williams-Jones, supra note 7, 
at 89 (discussing “[t]he social, ethical and policy implications of the commercialization of 
genetic testing for health related [sic] conditions . . .”). 
 9. See Henry T. Greely, The Uneasy Ethical and Legal Underpinnings of Large-Scale 
Genomic Biobanks, 8 ANN. REV. GENOMICS & HUM. GENETICS 343, 344-49 (2007). 
 10. 23andMe, Inc., 23andMe, Inc. Fact Sheet [hereinafter 23andMe, Inc. Fact Sheet], 
https://23andme.https.internapcdn.net/res/4843/pdf/factsheet.pdf (last visited Jan. 09, 
2010). 
 11. Anita Hamilton, TIME’s Best Inventions of 2008, TIME, Oct. 29, 2008, 
http://www.time.com/time/specials/packages/article/0,28804,1852747_1854493,00.html. 
 12. Id. 
 13. 23andMe, Inc. Fact Sheet, supra note 10. 
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Enterprise Associates, 23andMe is emblematic of a growing category of 
companies that actively seek to make genetic testing ubiquitous.14 
Under the heading “Genetics Just Got Personal,”15 23andMe offers tests 
that reveal patterns of hundreds of thousands of single-nucleotide 
polymorphisms (SNPs) across an individual’s genome.16  23andMe tests for 
over 600,000 SNPs through the Illumina HumanHap 550+ BeadChip17 
and makes the results—both the raw data and their analyses—available to 
customers through a password-protected website.18  The company offers two 
main categories of products: a genetic ancestry edition, and a health 
edition.19  The company provides several portals through which to interpret 
genetic results, including an application where customers learn about their 
SNP patterns (genotypes) and their associations with different ethnic 
populations.20 
23andMe is similar to other companies, including Bay area neighbor 
Navigenics, Inc. and the Icelandic company deCODE genetics.21  These 
companies use the same sequencing technology to offer similar tests,22 
though they distinguish themselves by price and test offerings.  In contrast to 
23andMe’s current fee of $399 (the lowest in the current market), 
Navigenics charges its customers $999 for individualized information on 
genetic risk for twenty-eight different complex diseases and syndromes, and 
promises to update customers with new information as genomic research 
advances.23  Navigenics “believe[s] that [it] can fundamentally improve 
 
 14. 23andMe, Inc., 23andMe Corporate Info, https://www.23andme.com/about/ 
corporate/ (last visited Jan. 09, 2010). 
 15. 23andMe, Inc., Home Page, https://www.23andme.com (last visited Jan. 09, 2010). 
 16. 23andMe, Inc., Frequently Asked Questions, How Does 23andMe Genotype My 
DNA?, https://www.23andme.com/you/faqwin/chip/ (last visited Jan. 09, 2010). 
 17. 23andMe, Inc., Genotyping Technology, https://www.23andme.com/more/geno 
typing/ (last visited Jan. 09, 2010). 
 18. 23andMe, Inc., Help FAQ, Who Can Access My Account?, https://www.23and 
me.com/you/faqwin/accountaccess/ (last visited Jan. 09, 2010). 
 19. See 23andMe, Inc., Store [hereinafter 23andMe Store], https://www.23andme.com/ 
store/ (last visited Jan. 09, 2010). 
 20. 23andMe, Inc., Help FAQ, What does the Odds Calculator Show?, https://www.23 
andme.com/you/faqwin/whatisincidence/ (last visited Jan. 09, 2010). 
 21. See Navigenics, Inc., Home Page, http://www.navigenics.com (last visited Jan. 09, 
2010); deCODE genetics, Home Page, http://www.decode.com (last visited Jan. 09, 2010). 
 22. Like 23andME, Navigenics and deCODE genetics both offer single nucleotide 
polymorphism (SNP) genotyping.  See 23andMe, Inc., Help FAQ, How Does 23andMe 
Genotype My Data?, https://www.23andme.com/you/faqwin/chip/ (last visited Jan. 09, 
2010); deCODE genetics, Scientific Services, http://www.decode.com/genotyping/index.php 
(last visited Jan. 09, 2010); Navigenics, Inc., The Science Behind the Navigenics Service, 
http://www.navigenics.com/static/pdf/Navigenics-TheScience.pdf (last visited Jan. 09, 2010). 
 23. 23andMe Store, supra note 19; Navigenics, Inc., Conditions We Cover, 
http://www.navigenics.com/visitor/what_we_offer/conditions_we_cover/ (last visited Jan. 09, 
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
2009] SOCIAL NETWORKING IN THE AGE OF PERSONAL GENOMICS 45 
health outcomes across the population by empowering people to act based 
on an understanding of their genetic predisposition for certain medical 
conditions.”24  This premise is central to the business of DTC personal 
genomic companies and it maintains that individuals are not only 
empowered by this form of self-knowledge, but that they are also expected 
to use their genetic risk profiles in the prevention of disease.25  23andMe 
builds on this emerging ethos, but in addition, offers a broader array of 
services, including non-medical information, or what the company provides 
in its “ancestry edition” product (e.g. tests for genetic lineage and traits such 
as wet or dry earwax).26  The success of 23andMe depends in part on 
creating a new class of ‘recreational genomics’.  Framing it with the 
pleasures of hobbies and entertainment, personal genome companies 
recast the weighty enterprise of genetic testing for disease—traditionally 
overseen by healthcare professionals—into a private matter between the 
consumer and the company from which she or he has purchased the 
information.27 
II.  LACK OF CONSENSUS ON DTC GENOMICS 
Personal genomics promises to leverage prognostic and predictive tools 
toward achieving personalized prevention and treatment of complex 
diseases,28 but despite the growing number of risk alleles reported in 
genome-wide association studies,29 some scientists are now skeptical about 
whether these DNA variants have clinical utility.30  One of the challenges of 
genome-wide association studies is the need for improved study designs that 
will ensure sufficient power to detect genes of modest risk while minimizing 
the potential of false-association signals from the testing of large numbers of 
 
2010); Navigenics, Inc., Our Genetic Testing, http://www.navigenics.com/visitor/what_we_ 
offer/our_tests/ (last visited Jan. 09, 2010). 
 24. Navigenics, Inc., Our Mission, http://www.navigenics.com/visitor/about_us/mission 
(last visited Jan. 09, 2010). 
 25. Fred Ledley, A Consumer Charter for Genomic Services, 20 NATURE BIOTECHNOLOGY 
767, 767 (2002). 
 26. See 23andMe, Inc., Ancestry, https://www.23andme.com/ancestry/lineage/ (last 
visited Jan. 09, 2010); 23andMe, Inc., Earwax Type – Sample Report, https://www.23and 
me.com/health/Earwax-Type/ (last visited Jan. 09, 2010). 
 27. See Catherine Nash, “Recreational Genetics”, Race and Relatedness, 24 
L’OBSERVATOIRE DE LA GENETIQUE 1, 1-7 (2005). 
 28. See, e.g., Dimitrios H. Roukos et al., Molecular Genetic Tools Shape a Roadmap 
Towards a More Accurate Prognostic Prediction and Personalized Management of Cancer, 6 
CANCER BIOLOGY & THERAPY 308, 311 (2007) (discussing the use of personalized treatments 
for cancer). 
 29. Pennisi, supra note 1, at 1842-43 (2007) (noting that in 2007 alone, “researchers 
linked variants of more than 50 genes to increased risk for a dozen diseases”). 
 30. See Hunter et al., supra note 3, at 105-106. 
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markers.31  Currently, there is a dearth of available sample sets, which has 
led to particular problems in the control of factors related to population 
substructure and false positive results.32 
With genome-wide association studies yielding few definitive results and 
many unknowns concerning the contribution of genomic information to 
relative risk for complex traits and diseases, several scholars, scientists, and 
health professionals have expressed concern that personal genomic 
products and services offer little value.33  These concerns have prompted 
scholars to suggest that personal genomic information needs to be 
interpreted and contextualized by clinicians and counselors in order to be 
meaningful to individuals.34  Even when an association between genetic 
variation and disease is statistically significant, this does not mean that it is 
clinically meaningful.35  “Moreover, simply knowing genetic risks and 
disease predispositions may not lead to better health decisions.  For some, it 
might lead to fatalism and reduced compliance with healthy choices.”36  
Some have argued that providing information directly to consumers without 
the help of experienced health professionals increases the chance that 
consumers will misinterpret their information and apply it inappropriately to 
their decisions regarding the management of their health.37  Therefore, the 
complexity of the concepts of risk, significance, validity, replication, and 
gene/environment interaction increase the likelihood that personal genomic 
information may lead to misunderstandings among consumers on how they 
should respond to their own results.38 
 
 31. See id. at 106. 
 32. See id. 
 33. See supra note 3. 
 34. See, e.g., Gollust et al., supra note 3, at 1764 (noting that consumers may not have 
the requisite knowledge to be able to understand the results and limitations of genetic tests). 
 35. Amy L. McGuire et al., The Future of Personal Genomics, 317 SCIENCE 1687, 1687 
(2007). 
 36. Id.  See also Wolfberg, supra note 3, at 545 (citing the chief of the Cancer Genetics 
Clinic at Baylor College of Medicine: “My biggest concern is that members of the public are 
getting tests that they don’t understand, and their physicians may not understand, and they 
may be making big decisions that are ill-informed”). 
 37. See, e.g., Gail H. Javitt, Policy Implications of Genetic Testing: Not Just for 
Geneticists Anymore, 13 ADVANCES CHRONIC KIDNEY DISEASE 178, 179-80 (2006); David 
Magnus et al., Genetic-Test Firms Must Follow Law, SAN JOSE MERCURY NEWS, July 11, 2008, 
at 19A (noting that individuals can easily allow misinterpretations of their test results influence 
their health decisions). 
 38. See, e.g., Javitt, supra note 37, at 178-79 (noting that genes’ interactions with 
environmental factors are largely unknown and that associations between genetic variations 
and disease are not necessarily clinically significant); Gollust et al., supra note 3, at 1763-64; 
Wasson et al., supra note 8, at 85 (noting throughout the danger that consumers may not 
understand their genetic test results and will make inappropriate health choices based upon 
erroneous notions). 
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Discussion of the ethical and social concerns over the validity and 
transparency of DTC genetic tests has focused primarily on products related 
to health.39  A body of literature on DTC marketing for breast cancer has 
generated calls for increasing scrutiny of corporate practices.40  Several 
professional organizations have produced position statements urging for 
greater oversight of DTC genetic testing, including the National Society of 
Genetic Counselors,41 the International Society of Nurses in Genetics,42 and 
the Secretary’s Advisory Committee on Genetics, Health and Society.43  In 
January 2007, the American Society of Human Genetics released a 
statement on DTC genetic testing in the U.S. urging: 1) greater transparency 
regarding information that consumers may require in order to make 
informed decisions about genetic testing; 2) increased education of health 
personnel regarding the clinical validity of DTC genetic tests; and 3) greater 
governmental oversight over both the validity of DTC tests and the use of 
commercial information concerning the value and limitations of the DTC 
tests.44  The trend in the scientific and bioethics literature seems to be that 
the majority of genetic tests currently marketed to the public may not meet 
minimum standards for clinical utility.45 
 
 39. See, e.g., Gollust et al., supra note 3, at 1762 (specifically focusing only on medical 
uses of genetic tests, and avoiding analyses concerning “paternity, identity, genealogy, and 
DNA banking”). 
 40. See, e.g., J. Mouchawar et al., Genetic Testing for Breast and Ovarian Cancer 
Susceptibility: Evaluating Direct-to-Consumer Marketing — Atlanta, Denver, Raleigh-Durham, 
and Seattle, 2003, 53 MORBIDITY & MORTALITY WKLY. REP. 603, 606 (2004) (arguing that 
“[c]ollaboration among public health agencies, health-care providers, the clinical 
laboratory/biotechnology industry, and professional organizations” is necessary “as genomics 
becomes more integrated into health promotion and disease prevention”). 
 41. See Position Statement, Nat’l Soc’y of Genetic Counselors, Direct to Consumer 
Genetic Testing (2007), http://www.nsgc.org/about/position.cfm. 
 42. See Position Statement, Int’l Soc’y of Nurses in Genetics, Provision of Quality Genetic 
Services and Care: Building a Multidisciplinary, Collaborative Approach Among Genetic 
Nurses and Genetic Counselors (Nov. 1, 2006), http://www.isong.org/about/ps_multi 
disciplinarygeneticcare.cfm. 
 43. See Letter from Reed V. Tuckson, Chair, SACGHS, to Tommy G. Thompson, Sec’y of 
Health & Human Serv. (Dec. 8, 2004), available at http://oba.od.nih.gov/oba/sacghs/ 
reports/DTCletter.pdf. 
 44. Kathy Hudson et al., ASHG Statement on Direct-to-Consumer Genetic Testing in the 
United States, 81 AM. J. HUM. GENETICS 635, 636-37 (2007). 
 45. See, e.g., Javitt, supra note 37, at 178-79 (highlighting the lack of oversight and 
transparency, which make it difficult to gauge validity and reliability); Wasson et al., supra 
note 8, at 84 (stating that the reliability and validity of DTC genetic tests are difficult to 
ascertain); Magnus et al., supra note 37, at 19A (noting that the tests do not take into account 
such risk factors as diet, medication, and exercise). 
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III.  BIOSOCIALITY AND THE SHARING OF PERSONAL GENOMIC INFORMATION 
Despite concerns over the utility of personal genomics, DTC personal 
genomic companies have expanded their services by essentially claiming 
that the public desires direct access to personal genomic information and 
that the industry fills that gap by providing expert knowledge and leadership 
in research on personalized medicine.  This expansion has led to the 
development of online sharing tools, collaborations with social networking 
platforms, and the creation of online, company-sponsored research 
communities.  In considering the ethical and regulatory implications of 
social networking around personal genomic information, it will be important 
to consider not only the benefits (and risks) applicable to individual 
consumers as described above, but their impacts on larger social groups 
formed by the sharing of personal genomic information. 
In its commitment to connecting individuals around genomics, 23andMe 
encourages its consumers to share their results with family members, friends, 
and others via their website.46  Towards this end, 23andMe has created 
online tools allowing its consumers to instantaneously compare their genes 
with others who likewise agree to share information.47  This exchange may 
occur through one-to-one comparisons or through the establishment of 
groups.48  For example, a 23andMe customer may want to connect with a 
friend who also has a 23andMe account in order to share their individual 
risks for stomach cancer.  To do so, she would only need to send a request 
to share to her friend using the 23andMe platform, and upon consent, they 
may discover that they have a 95.2% similarity in the hundreds of SNPs that 
are associated with this disease.49  If the two friends wanted to create a 
group of friends with which to share information, they would only need to 
make the requests and designate their “friends” as sharers and 23andMe 
will provide graphics that will allow them to see the relative percent similarity 
or dissimilarity within the group.50 
The potential for social networking is amplified through other company-
provided online tools such blogs and dedicated community webpages, 
where consumers with similar genomic profiles may congregate in virtual 
space to meet and carry on online discussions.51  For example, individuals 
who show a higher genetic predisposition to Parkinson’s disease may 
 
 46. 23ANDME, INC., GETTING STARTED GUIDE 8 (2008) (noting that members can choose 
to share their genomes with other members through 23andMe’s “Genome Sharing” 
application). 
 47. Id. 
 48. Id. at 12. 
 49. See id. 
 50. See id. 
 51. 23ANDME, INC., supra note 46, at 8-9. 
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converse online with others who have received similar information.52  For 
example, 23andMe recently announced the organization of their Pregnancy 
Community, as seen in Figure 1 below.  Suggesting an “instant circle of 
friends,” 23andMe creates a dedicated portal for pregnant consumers to 
discuss questions they may have about their genetic profiles.53 
FIGURE 1.  PREGNANCY COMMUNITY: A “CIRCLE OF FRIENDS” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Such online tools provide the infrastructure for new social formations 
through a process that has been referred to as “biopolitics.”  Biopolitics 
describes the use of scientific understanding of life into the field of politics 
and governance.54  Historically, this necessitated the inclusion of political 
authorities and scientific experts—such as physicians, urban planners, and 
others, who could administer, modify, control, and regulate individual 
behavior for the collective good.55  The rise of genetics and the emerging 
coupling of genetic tests with “wellness programs” and self-care provide a 
powerful framework for what some have described as “biological 
 
 52. See, e.g., 23andMe, Inc., 23andMe Parkinson’s Community: Strength in Numbers, 
https://www.23andme.com/pd/ (last visited Jan. 08, 2010). 
 53. 23andMe, Inc., Pregnancy Community, https://www.23andme.com/pregnancy/ (last 
visited Jan. 09, 2010). 
 54. MICHEL FOUCAULT, THE HISTORY OF SEXUALITY: VOLUME I: AN INTRODUCTION 139-40 
(1978). 
 55. See id. at 139-41. 
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citizenship.”56  This framework merges with the narrative of DTC personal 
genomics in that knowing one’s genes and related risk profiles provides the 
basis for the modification of behavior and the adoption of preventative 
health despite the explicit rejection by the company in its customer 
agreements and informed consent forms that its genetic testing products 
constitute diagnostic or health-related information.57  By creating virtual 
space for individuals to identify and connect through common genomic 
information, the company provides the architecture for self-governance of 
health that promotes engagement with and management of genomic risk.58 
In the emerging era of DTC personal genomics, social networking could 
potentially extend beyond any one individual to the creation of biosocial 
groups that demand a voice in shaping new genetic technologies.  Scholars 
have already shown the power of technological developments in creating 
collective identity.  An example is found in Benedict Anderson’s analysis of 
the impact of the printing press in creating “imagined communities” that no 
longer tethered groups by geographic proximity, but allowed the idea of 
community to be created through shared circuits of information flow.59  
Similarly, the Internet and the development of online tools have impacted 
the flow of personal genomic information between individual actors.60  This 
will require serious consideration of what is at stake for consumers, 
companies, and the communities that are forged around the sharing of 
personal genomics.  Personal genomic information must be understood in a 
framework of collective identity in order to identify fundamental ideals and 
values that operate in the coalescence of virtual communities.  Building on 
 
 56. See generally Nikolas Rose & Carlos Novas, Biological Citizenship, in GLOBAL 
ASSEMBLAGES: TECHNOLOGY, POLITICS, AND ETHICS AS ANTHROPOLOGICAL PROBLEMS 439, 439-
58 (Aihwa Ong & Stephen J. Collier, eds., 2005) (describing how scientific and technological 
advances are changing the concept of using biology as a classification of citizenship). 
 57. See 23andMe, Inc., Consent and Legal Agreement [hereinafter 23andMe Legal 
Agreement], https://www.23andme.com/about/consent (last visited Jan. 09, 2010) (noting 
that “the 23andMe Personal Genome Service is not a test or kit designed to diagnose disease 
or medical conditions, and it is not intended to be medical advice”). 
 58. See 23andMe, Inc., Core Values, https://www.23andme.com/about/values (last 
visited Jan. 09, 2010). 
 59. BENEDICT ANDERSON, IMAGINED COMMUNITIES: REFLECTIONS ON THE ORIGIN AND 
SPREAD OF NATIONALISM 54 (rev. ed. 1991). 
 60. See Matthew R. G. Taylor, Amy Alman & David K. Manchester, Use of the Internet by 
Patients and Their Families to Obtain Genetics-Related Information, 76 MAYO CLINIC PROC. 
772, 775 (2001) (noting that “[t]he Web for [genetics-related information] provides physicians 
and patients equal access to information.  Patients and their families can now rapidly and 
conveniently access information (and misinformation) about their genetic disorder with the 
click of a mouse”). 
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Gibbon’s work on the “ethical value of community,”61 questions that probe 
the authority, flexibility, and the strategic co-construction of community by 
and through DTC genomic companies will be essential in order to fully 
consider the impact of the DTC personal genomic market on the trajectory 
of genomic medicine. 
IV.  THE BLURRING BOUNDARY BETWEEN CONSUMER AND RESEARCH PARTICIPANT 
The use of social networking tools have been increasingly used by 
organizations interested in influencing the course of biomedical research.  
For example, in 2004 the non-profit company, PatientsLikeMe, was 
launched by three MIT engineers interested in using large-scale online 
commercial applications to create communities of patients, health 
professionals, and organizations.62  A fundamental goal of the company 
was to provide patients access to others who could provide information and 
share experiences about specific diseases of interest.63  Under the motto of 
“patients helping patients live better everyday,”64 the online site provides 
infrastructure for virtual communities organized around a broad range of 
diseases and conditions, including amyotrophic lateral sclerosis (ALS), 
HIV/AIDS, and post-traumatic stress disorder.65  Undergirding 
PatientsLikeMe’s approach is an “Openness Philosophy,” that emphasizes 
that “openness is a good thing.”66  Asserting that transparency is critical for 
the greater good, the company states that “the Internet can democratize 
patient data and accelerate research like never before.  Furthermore, we 
believe data belongs to you the patient to share with other patients, 
caregivers, physicians, researchers, pharmaceutical and medical device 
companies, and anyone else that can help make patients’ lives better.”67 
Echoing a similar goal to “dramatically accelerate the pace of genetics 
research,” 23andMe unveiled its new research arm, 23andWe in the spring 
 
 61. See Sahra Gibbon, Community, the Commons and Commerce: the Ownership of 
BRCA Genes and Genetic Testing, in CONTESTING MORALITIES: SCIENCE, IDENTITY, CONFLICT 
43, 54 (Nanneke Redclift ed., 2005) (analyzing the use of “moral communities” in a 
discussion of commercial genetic testing in the UK). 
 62. PatientsLikeMe.com, About Us, http://www.patientslikeme.com/about (last visited Jan. 
09, 2010). 
 63. Id. 
 64. Id. 
 65. PatientsLikeMe.com, Home Page, http://www.patientslikeme.com/ (last visited Jan. 
09, 2010). 
 66. PatientsLikeMe.com, Openness Philosophy, http://www.patientslikeme.com/about/ 
openness (last visited Jan. 09, 2010). 
 67. Id. 
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of 2008.68  This program focuses on the company’s well-publicized goal to 
actively engage with consumers who wish to participate in population-based 
genetic research.  Stating that “23andMe isn’t just about you,” the company 
explains that 23andWe “gives customers the opportunity to leverage their 
data by contributing it to studies of genetics.”69  The company states that 
“[w]ith enough data [it] can produce revolutionary findings that will benefit 
us all.”70 
In Figure 2 below, 23andMe highlights a personalized page which 
contains an individual’s genetic data in the context of muscle 
performance.71  Describing what the company identifies as gene ACTN3, 
the page describes how variation in the presence or absence of this SNP 
may contribute to whether a customer is more likely to be a sprinter or 
marathoner.72  With an account, the customer is able to see his own data in 
comparison with the “23andWe Community,” as indicated in the inset box 
titled with the query, “Tortoise or Hare?”73 
When signing up for 23andMe services, consumers are informed that 
their samples will become part of an anonymized database controlled by the 
company.74  To participate in the 23andWe community, consumers are 
asked to sign up.75  Consenting consumers are able to share their results 
with others and may be asked to participate in studies sponsored in 
collaboration with various researchers through collaborative relationships 
between 23andMe and other institutions and organizations.76 
 
 68. Press Release, 23andMe, Inc., “23andWe” Mission: To Dramatically Accelerate the 
Pace of Genetics Research, (May 29, 2008), available at https://www.23andme.com/about/ 
press/20080529/. 
 69. 23andMe, Inc., 23andWe Research [hereinafter 23andWe Research], https://www.23 
andme.com/research (last visited Jan. 09, 2010). 
 70. Id. 
 71. 23andMe, Inc., Muscle Performance—Sample Report, https://www.23andme.com/ 
health/Muscle-Performance/ (last visited Jan. 09, 2010). 
 72. Id. 
 73. 23andWe Research, supra note 69 (from Research page, click on “view slideshow”; 
go to slide number 5). 
 74. See 23andMe Legal Agreement, supra note 57. 
 75. See 23andWe Research, supra note 69. 
 76. 23andMe Legal Agreement, supra note 57. 
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FIGURE 2.  23ANDWE PARADIGM FOR GENOMIC RESEARCH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Although the DTC personal genome companies emphasize that genetic 
data collected will never be sold, several have said they might consider 
partnerships with academic researchers or nonprofit drug developers in the 
future as a way of recruiting subjects for clinical trials and collecting 
additional information for research.  For example, 23andWe and 
PatientsLikeMe have announced a collaboration focused on research on 
Parkinson’s Disease through which PatientsLikeMe will recruit individuals to 
be genotyped by 23andMe and then participate in company-sponsored 
research.77  23andMe even has its own Facebook page.78  Such social 
networking opportunities allow for instantaneous and pervasive sharing of 
personal genomic information in the course of routine, day-to-day 
socializing practices and demands research on the possible implications of 
these new social circuits. 
 
 77. See Press Release, PatientsLikeMe.com, PatientsLikeMeTeams Up With 23andMe to 
Help Parkinson’s Patients (June 9, 2009), http://www.patientslikeme.com/press/20090609/ 
17-patientslikeme-teams-up-with-23andme-to-help-parkinsons-patients?disease_tag=hiv. 
 78. Facebook, 23andMe, http://www.facebook.com/23andMe?v=info (last visited Jan. 
09, 2010). 
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The coalescence of consumer groups around genomic information and 
disease is an emerging trend.  Over the last several decades advocacy 
groups have proliferated79 and provided critical funding for biomedical 
research.  With the help of the Internet, public advocacy groups have 
created relationships with scientists and clinicians that have had a direct 
impact on the trajectory of research80 by providing greater input in research 
questions and design, recruiting participants, and catalyzing studies 
responsive to patient experiences and needs.81  These patient groups have 
produced what some scholars have identified as “new forms of democratic 
participation.”82 
However, as the relationship between patient groups and industry 
partners has become more intertwined in recent years, there is concern over 
potential conflicts of interest.  Stating the need for oversight, some have 
cautioned against adopting valueless or even harmful products or 
interventions that are promoted by industry through the use of patient 
voices.83  In a context of population-based genomic research and the 
 
 79. See, e.g., Amy Dockser Marcus, Advocacy Overload? Activists Seek to Unify Efforts of 
Groups Targeting Diseases; A Brain-Tumor Collaborative, WALL ST. J., Oct. 10, 2006, at D1 
(noting that for brain tumors, there are 141 different patient-advocacy groups for the 43,000 
new diagnoses each year.  That means there is roughly one advocacy group for every 305 
new patients diagnosed with primary brain tumors). 
 80. See generally NIKOLAS ROSE, THE POLITICS OF LIFE ITSELF: BIOMEDICINE, POWER, AND 
SUBJECTIVITY IN THE TWENTY-FIRST CENTURY 148 (2007) (noting that today’s patient 
organizations are not simply focused on increased funding, but on actively “shaping the 
direction of science”); Sharon F. Terry et al., Advocacy Groups as Research Organizations: 
The PXE International Example, 8 NATURE REVIEWS GENETICS 157, 157-58 (2007) (noting that 
advocacy organizations are becoming more involved in research by becoming more active in 
areas like translational research); Nancy Tomes, The Patient as a Policy Factor: A Historical 
Case Study of the Consumer/Survivor Movement in Mental Health, 25 HEALTH AFF. 720, 720, 
724 (2006) (analyzing the importance of consumer/survivor groups in the area of mental 
health); John W. Walsh et al., A Review of the Alpha-1 Foundation: Its Formation, Impact, 
and Critical Success Factors, 51 RESPIRATORY CARE 526, 526, 530 (2006) (discussing one 
specific patient advocacy organization and its influence on research and clinical care for its 
targeted community). 
 81. See Laura Landro, The Growing Clout of Online Patient Groups, WALL ST. J., June 
13, 2007, at D1.  See also Jean Cohen, The Role of Patients’ Associations in Assisted 
Reproduction Treatment, 13 REPROD. BIOMED. ONLINE 447, 447-48 (2006). 
 82. Deborah Heath, Rayna Rapp & Karen-Sue Taussig, Genetic Citizenship, in A 
COMPANION TO THE ANTHROPOLOGY OF POLITICS 152 (David Nugent & Joan Vincent eds., 
2004). 
 83. See Ezekiel J. Emanuel, Drug Addiction: Cancer in the Courts, NEW REPUBLIC 9, 9-12 
(2006) (discussing how allowing access to unproven treatments provides false hope to 
terminally ill patients). 
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ongoing challenges of recruitment of individuals into studies,84 models of 
openness through social networking, as evident in companies like 23andMe 
and PatientsLikeMe, demand careful consideration.  These conflicts are not 
addressed in the current arena of DTC personal genomics. 
In the summer of 2009, 23andMe built on their efforts of 23andWe by 
unveiling a new program entitled, “The 23andMe Research Revolution.”85  
The Research Revolution initiative is aimed at enrolling 1,000 consumers 
into ten studies that focus on the following diseases and conditions: 
migraines, psoriasis, rheumatoid arthritis, severe food allergies, celiac 
disease, lymphoma and leukemia, multiple sclerosis, amyotrophic lateral 
sclerosis (ALS), epilepsy, and testicular cancer.86  At a discounted rate of 
$99, consumers receive most of the genetic information on diseases and 
traits entitled to full price customers—except for ancestry information—and 
are able to share information using the company web site.87  Also, unlike 
customers paying the $399 price, Research Revolution participants do not 
have access to their raw genetic data.88  As Figure 3 below from the 
Research Revolution webpage illustrates, customers are asked to take 
surveys that ask questions about lifestyle and behavior.89  Rooting this 
product firmly in future societal benefit, 23andMe states that participating 
“could lead to better healthcare for everyone.”90  A challenge for DTC 
genomic research activities is the incongruous position of companies in that 
the genetic information they are providing is not “medical” or “health 
related,” and yet, the same information is used as the basis for galvanizing 
the consumer base to participate in medical research. 
 
 84. See, e.g., Mark A. Hall, et al., Concerns in a Primary Care Population about Genetic 
Discrimination by Insurers, 7 GENETICS MED. 311 (2005) (analyzing public concerns about 
genetic discrimination and its influence on research participation). 
 85. 23andMe, Inc., The 23andMe Research Revolution Overview [hereinafter 23andMe 
Research Revolution Overview], https://www.23andme.com/researchrevolution/overview/ (last 
visited Jan. 09, 2009). 
 86. 23andMe, Inc., The 23andMe Research Revolution, https://www.23andme.com/ 
researchrevolution/ (last visited Jan. 09, 2010). 
 87. 23andMe, Inc., Compare Services, https://www.23andme.com/researchrevolution/ 
compare/ (last visited Jan. 09, 2010). 
 88. Id. 
 89. See 23andMe Research Revolution Overview, supra note 85. 
 90. Id. (go to Overview page; click on “view slideshow”; go to slide 7, The Benefits of 
Participating in 23andMe Research). 
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FIGURE 3.  “RACE TO 1000” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
An important ethical question prompted by these new formations is 
whether DTC genomic consumers may also be considered research 
subjects.  If so, the next question is whether companies must fulfill the same 
responsibilities and obligations to their consumers as would be expected in 
traditional contexts of genomic research.  Are consumers ongoing vested 
partners in the research activities of 23andMe or are they “altruists,” who 
are donating their samples and genetic data for the potential benefit of 
general knowledge?  What type of assurances are there that the anonymity 
of genetic information will be safeguarded against genetic technologies 
aimed at identifying increasingly specific genetic variation where individual 
identity may be inferred even when personal information has been de-linked 
from samples?  What obligations does the company have to its consumers 
to inform them of the type of research being conducted using consumer 
samples? 
Research now indicates that individual SNP profiles can be identified 
within pooled datasets.91  Homer et al. analyzed complex mixes of genomic 
DNA using high-density SNP genotyping microarrays.92  This allowed them 
to accurately identify individuals from aggregated genetic data, leading 
them to conclude that individuals can be identified in de-identified datasets 
 
 91. Nils Homer et al., Resolving Individuals Contributing Trace Amounts of DNA to Highly 
Complex Mixtures Using High-Density SNP Genotyping Microarrays, 4 PLOS GENETICS 1, 1-2 
(2008), available at http://www.plosgenetics.org/article/info%3Adoi%2F10.1371%2Fjournal. 
pgen.1000167. 
 92. Id. at 1. 
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of more than 1,000 people.93  In response, the NIH and other institutions, 
including the Wellcome Trust Case Control Consortium in England and the 
Broad Institute of MIT and Harvard in Boston, removed previously publicly 
available aggregated data and have established a use policy that requires 
the protection of individual identity.94  Such developments are salient to the 
creation of DTC personal genomics where DNA datasets may be distributed 
for genomic research.  Ethical and social concerns over the security and 
confidentiality of personal information volunteered by consumers require 
greater scrutiny in order to ensure that consumers’ genetic information is 
protected when it is shared for research. 
V.  THE NEED FOR EMPIRICAL RESEARCH 
Despite the proliferation of companies that seek to bring personal 
genomic services and products to market, there is little consensus in the 
scientific literature over the clinical utility of many of the genome-wide study 
results published thus far.  However, it is also evident that the once 
seemingly elusive $1000 genome will be a reality in the near future and that 
routine whole genome sequencing may soon be ubiquitous.  How meaning 
will be inferred to this abundance of personal genetic information and in 
what manner it will be understood will be critical to how genomic 
information becomes integrated into healthcare and social relationships.  A 
serious challenge to efforts to fully understand the ethical and social 
implications of DTC personal genomics is a critical gap in empirical 
research on the perspectives and practices of two important stakeholder 
groups: the companies who provide genetic ancestry products and the 
individuals who consume them. 
A 2007 study by Goddard et al., assessed consumer and physician 
awareness of genomic tests and consumer use of such tests via two national 
surveys.95  They found that consumers who were aware of the tests tended to 
be young and educated with a high income.96  Given the costs of personal 
genomic tests, it would seem that the test results reflect the population that 
would be the most likely to purchase the tests.  However, as yet, there has 
been little research that reveals much more of who really are the consumers 
of DTC personal genomics tests.  Studies that investigate not only who DTC 
personal genomic consumers are and perhaps more importantly, how 
individuals interpret and utilize their personal genomic information in daily 
decisions and everyday practice, will be essential. 
 
 93. Id. at 2. 
 94. NAT’L INST. OF HEALTH, NIH BACKGROUND FACT SHEET ON GWAS POLICY UPDATE 1-2 
(2008), http://grants.nih.gov/grants/gwas/background_fact_sheet_20080828.pdf. 
 95. Goddard et al., supra note 2 at 511. 
 96. Id. at 513. 
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As social networking through online tools and platforms expands, it will 
be important to assess how consumers might be protected against potential 
discriminatory use of personal genomic information.  In 2008, Congress 
passed the Genetic Information Nondiscrimination Act (GINA), which offers 
broad protections against genetic discrimination in the provision of health 
insurance and decisions regarding employment.97  Although this statute fills 
an important and long-standing gap in legal protections against genetic 
discrimination, there remain several limitations to the legislation.  Such 
limitations include cases where genetic information is obtained “through 
publicly-available information” or it is “inadvertently obtained” through 
general searches on the internet.98 
Focusing on genetic information as the unit of analysis, an examination 
of the life-course of personal genomic information as it is shared with family 
members, health professionals, online communities, and researchers, will 
illuminate the impact of DTC personal genomics on the current regulatory 
landscape.  Questions that will be important to address are: Who are the 
people who are using online tools and platforms to share their personal 
genomic information, and what genetic information is being shared?  What 
impact does sharing information have on the behaviors and decisions of 
primary and secondary actors?  What are the similarities and differences 
among individuals who share their information and those who volunteer to 
participate in DTC-sponsored research efforts?  Detailed analyses 
concerning how personal genomic information “travels” to different 
individuals and institutions through the web will be important in creating 
regulatory safeguards against potential abuse. 
Another important area of research will be to investigate the prevailing 
assumptions that have ushered in this new era of personal genomics and 
served as rationale for emerging markets.  Key questions will be to 
interrogate what “democratization of the genome” means for healthcare 
and what will be the future of large-scale population-based genetic 
research?  Such a study would contribute a more informed assessment of 
the rights and responsibilities of companies and consumers who enter into 
research relationships.  It will help contribute to the understanding of how 
regulations can address the broader ethical implications of consumer 
participation in DTC-sponsored research communities, and also explore the 
long-term significance of DTC genetic testing for the larger landscape of 
genomic medical research. 
 
 97. Genetic Information Nondiscrimination Act of 2008 (GINA), Pub. L. No. 110-233, 
122 Stat. 881 (2008) (to be codified at 42 U.S.C. 2000ff et. seq. in scattered sections of 26 
U.S.C., 29 U.S.C., and 42 U.S.C.). 
 98. § 202-205.  See also Regulations Under the Genetic Information Nondiscrimination 
Act of 2008, 74 Fed. Reg. 9056, 9063 (proposed Mar. 2, 2009). 
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In an era of increasingly efficient genotyping technologies, DTC 
genomic companies have emerged as new regimes of biosociality where 
personal genetic information may reconstitute human identity and create 
new networks of social relationships.  Personal genetic information and the 
practice of comparing one’s own profile to others has the potential to create 
biosocial groups that ultimately serve to overcome the “nature/culture split” 
where biology becomes inherent to both our social identities and our 
positions in the world.99  As personal genomic information is used in novel 
ways, it will be critical to put in place effective safeguards and policies.  
Successful translation of personal genomic information will depend on the 
adaptability of current models towards ethical oversight in considering new 
commercial, clinical, and research trajectories of the personal genome era. 
  
 
 99. Paul Rabinow, Artificiality and Enlightenment: From Sociobiology to Biosociality, in 
INCORPORATIONS, 234, 241-44 (Jonathan Crary & Sanford Kwinter eds., 1992). 
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